- GeneTether Therapeutics (GTTX) has successfully closed its initial public offering and concurrent non-brokered private placement
- A total of 7,500,000 units were sold at a price of $0.60 per unit for aggregate gross proceeds of $4,500,000
- The company’s common shares are expected to commence trading on the CSE under the symbol GTTX on or about March 30, 2022
- GeneTether Therapeutics is an innovative genetic medicines company
- Shares of GeneTether Therapeutics Inc. (GTTX) opened trading at C$0.67
GeneTether Therapeutics (GTTX) has successfully closed its initial public offering and concurrent non-brokered private placement.
A total of 7,500,000 units were sold at a price of $0.60 per unit for aggregate gross proceeds of $4,500,000.
The company’s common shares are expected to commence trading on the CSE under the symbol GTTX on or about March 30, 2022.
GeneTether CEO Roland Boivin sat down with Dave Jackson to discuss the news.
GeneTether is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction. The company is leveraging its platform technology to develop curative therapies for the treatment of rare genetic diseases.
Shares of GeneTether Therapeutics Inc. (GTTX) opened trading at C$0.67
